FINWIRES · TerminalLIVE
FINWIRES

UBS Downgrades Crinetics Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $85 From $55

By

Crinetics Pharmaceuticals (CRNX) has an average rating of hold and mean price target of $85.50, according to analysts polled by FactSet.

What else is happening in Research?